John Kilhefner

John Kilhefner

Senior Managing Editor, Lango Franchise

John Kilhefner is Senior Managing Editor of the Luke Lango franchise, which includes Hypergrowth Investing, Innovation Investor, Crypto Investor Network, and more.
Kilhefner has contributed to media such as Benzinga, The Hill, Tip Ranks, Unwinnable, The Arcade Review, Five Out of Ten magazine, and ZAM. He has appeared in U.S. News and World Report, Kotaku, USA Today, and Game Developer.
He now runs his own creative agency focused on tech and cybersecurity, called Skellator, LLC.
Learn more here

Recent Articles

Novavax, Inc.: NVAX Stock Gets Gutted — Can It Still Double?

By John Kilhefner, Senior Managing Editor, Lango Franchise

Novavax, Inc. (NASDAQ:NVAX) is leading the biotech charge downward today on dismal earnings that left investors questioning the bull case.

Endo International Plc: ENDP Stock Gets a Helping Hand from Par Pharmaceutical

By John Kilhefner, Senior Managing Editor, Lango Franchise

ENDP stock is surging 20%-plus, as the company's Par Pharma acquisition translates into a bigger-than-expected sales and earnings beat.

Health Insurance Innovations Inc (HIIQ): Micro-Cap Roars on Earnings Beat

By John Kilhefner, Senior Managing Editor, Lango Franchise

Health Insurance Innovations (HIIQ) wafts up big-time after boffo earnings. But expect many investors to start taking profits sooner than later.

LendingClub Corp: LC Stock Slides as CFO Skips Town

By John Kilhefner, Senior Managing Editor, Lango Franchise

LC stock is selling off in Monday's after-hours action after LendingClub missed on earnings and shed another high-level exec.

Tyson Foods, Inc (TSN) Beats on All Fronts, Market Undecided

By John Kilhefner, Senior Managing Editor, Lango Franchise

Tyson Foods, Inc. (NYSE:TSN) posted a sizable earnings beat, but the market's exuberance waned soon after. Could sentiment in the sector be diminishing?

Horizon Pharma PLC: HZNP Stock Pops After HUGE Earnings Beat

By John Kilhefner, Senior Managing Editor, Lango Franchise

HZNP stock beats earnings expectations by a wide margin, as Horizon Pharma aims to corner the rare-disease market.

Biogen Inc (BIIB) Tacks on $7B in Market Value on Buyout Talk

By John Kilhefner, Senior Managing Editor, Lango Franchise

Biogen Inc (NASDAQ:BIIB) just made a huge move out of thin air Tuesday evening, spiking 9.5% to $330 as of this writing. Until the surge, BIIB…

GrubHub Inc: GRUB Stock Investors Pig Out After Earnings Beat

By John Kilhefner, Senior Managing Editor, Lango Franchise

GrubHub Inc (GRUB) shares are up near 30% after reporting a tasty top- and bottom-line beat. But is its growing valuation sustainable?

Ariad Pharmaceuticals, Inc.: ARIA Stock Squeezes the Shorts on Blowout Quarter

By John Kilhefner, Senior Managing Editor, Lango Franchise

Ariad Pharmaceuticals (ARIA) surprised investors and short-sellers alike by hitting on all cylinders in its earnings report.

Sequenom, Inc.: SQNM Stock Soars on LabCorp Bid

By John Kilhefner, Senior Managing Editor, Lango Franchise

Sequenom (SQNM) stock holders just had their best day in years as LabCorp (LH) acquires the company for its extensive women's health testing suite.

Load More